Experts Provide Insight on the Biggest Advances in Oncology in 2019

Jan 1, 2020

By OncLive Staff

In Partnership With:

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Related Videos

Related Content

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent

January 26th 2023

Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

January 2nd 2023

Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

January 25th 2023

Ripretinib Demonstrates Clinical Benefit in KIT Exon 11, 17/18–Mutated Advanced GIST

January 24th 2023

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent

January 26th 2023

Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

January 2nd 2023

Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

January 25th 2023

Ripretinib Demonstrates Clinical Benefit in KIT Exon 11, 17/18–Mutated Advanced GIST

January 24th 2023

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent

January 26th 2023

Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

January 2nd 2023

Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

January 25th 2023

Ripretinib Demonstrates Clinical Benefit in KIT Exon 11, 17/18–Mutated Advanced GIST

January 24th 2023

Related Content

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent

January 26th 2023

Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates

January 2nd 2023

Bavituximab Plus Pembrolizumab Elicits Responses in Untreated Advanced HCC

January 25th 2023

Ripretinib Demonstrates Clinical Benefit in KIT Exon 11, 17/18–Mutated Advanced GIST

January 24th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.